Valneva (NASDAQ:VALN) Shares Gap Up – Time to Buy?

Valneva SE (NASDAQ:VALN) shares gapped up before the market opened on Monday . The stock had previously closed at $7.44, but opened at $8.01. Valneva shares last traded at $7.77, with a volume of 53,450 shares.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price target on shares of Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th.

Valneva Trading Down 5.1 %

The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The company has a market cap of $602.14 million, a PE ratio of -57.00 and a beta of 1.98. The company has a fifty day simple moving average of $5.41 and a two-hundred day simple moving average of $5.67.

Institutional Trading of Valneva

Hedge funds have recently added to or reduced their stakes in the company. ABC Arbitrage SA purchased a new stake in shares of Valneva in the 4th quarter valued at approximately $84,000. AlphaCentric Advisors LLC grew its stake in shares of Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock worth $717,000 after purchasing an additional 29,748 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after buying an additional 30,859 shares during the last quarter. Institutional investors and hedge funds own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.